Huge progress has been made in therapeutic strategies that target the primary defect of dystrophin deficiency, such as gene replacement, exon skipping, and readthrough therapies, as well as in strategies that target the secondary pathology of DMD, such as novel dissociative steroid and myostatin inhibitors. This evidence concerns the gene MSTN and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.